Skip to main content
Ipsen Home Page
Press shift tab to select search category
Loading...
  • Newsroom arrow down
      < Back
    • Newsroom
    • Press Releases
    • Media Updates
    • emc易倍官网入口Media Resources
    • emc易倍官网入口Media Contacts
    • Subscribe
  • Investors arrow down
      < Back
    • Investors
    • Investors
    • emc易倍官网入口Financial Results
    • Annual Reports & Regulated Information
    • emc易倍官网入口Investor Events & Financial Calendar
    • Shareholder Information
    • Subscribe
    • Ratings & Bonds
  • Careers arrow down
      < Back
    • Careers
    • Careers
    • Working at Ipsen
    • Culture
    • Job Search
  • Contacts arrow down
      < Back
    • Contacts
    • Contacts
    • Our Locations
    • Report Side Effects
    • Subscribe
  • Press shift tab to select search category
    Loading...
  •         EN  arrow_down
    • English EN
    • Fran?ais FR
  •  Global
    <
    • Global EN FR
    • Annual Report EN FR
    • Americas
    • Asia Pacific
    • Europe
    • emc易倍官网入口Middle East & Africa
    • Brazil
    • Canada
    • emc易倍官网入口 United States
    • Mexico
    • Colombia
    • Australia
    • China
    • Singapore
    • emc易倍官网入口 South Korea
    • emc易倍官网入口 Japan
    • Belgium
    • Ukraine
    • UK
    • Germany
    • emc易倍官网入口 France
    • Nordics
    • Greece
    • emc易倍官网入口 Italy
    • Netherlands
    • Spain
    • Poland
    • Russia
    • Czech Republic
    • Romania
    • emc易倍官网入口 Hungary
    • emc易倍官网入口 Slovakia
    • Switzerland
    • emc易倍官网入口 Austria
    • UAE & Gulf
    • Saudi Arabia
  • Home
  • Company
      < Back
    • Company
    • Company
    • emc易倍官网入口Leadership
    • History
    • emc易倍官网入口Fondation Ipsen
  • Expertise
      < Back
    • Expertise
    • Oncology
    • Rare Disease
    • Neuroscience
    • Medicines
  • Science
      < Back
    • Science
    • Science
        < Back
      • Science
      • Oncology
      • Rare Disease
      • Neuroscience
    • Profiles
    • Partnering
        < Back
      • Partnering
      • Therapeutic focus
      • Meet the team
    • Clinical Trials
        < Back
      • Clinical Trials
      • emc易倍官网入口Lay Summaries
      • emc易倍官网入口Find Clinical Trials
    • emc易倍官网入口Pipeline
  • Sustainability
      < Back
    • Sustainability
    • Sustainability
    • Environment
    • Patients
    • People
    • emc易倍官网入口Governance
    • Our Standards
  • Patients
      < Back
    • Patients
    • Patients
    • Together for Oncology
    • Together for Rare Disease
    • Together for Neuroscience
    • Collaborate with us
  • Stories
  1. Home
  2. emc易倍官网入口Newsroom – Newsroom – Subscribe to Ipsen News

emc易倍官网入口

IPN price

€161.60

 €-0.30 (-0.19%)

  • emc易倍官网入口Media Resources
  • Annual Report
  • Contacts
  • Our Locations
Ipsen logo
LinkedIn Instagram Facebook Youtube
  • Terms and Conditions
  • Cookie Policy
  • Global Privacy Policy

? Ipsen Pharma. All rights reserved - 2026

You are now leaving the Ipsen group global website. To continue, please click on Continue?

Continue
We value your feedback

How easy was it to navigate Ipsen website and locate the information you were seeking?







2026-08-09 17:58:20